Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of Fexuclue Administration in Erosive Esophagitis
NCT04613895Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Nov 2020
- Primary completion
- May 2021
- Countries
- 1
01
Overview
Randomised, open-label trial of fexuprazan in erosive esophagitis (EE) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Healing rate of mucosal breaks at 4 weeks. Status: unknown.
02
Drugs
fexuprazan
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT04613895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04613895.